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Abstract
Background: Human herpesvirus 8 (HHV-8) is the etiological agent for Kaposi Sarcoma, which occurs especially in HIV-
infected subjects. HHV-8 infection and its clinical correlates have not been well characterized in recently HIV-1-infected
subjects, especially men who have sex with men (MSM).
Methodology/ Principal Findings: We assessed the HHV-8 seroprevalence, clinical correlates, and incidence after one year
of follow-up in a cohort of 228 recently HIV-1-infected individuals, of whom 83.6% were MSM, using indirect
immunofluorescence assay. The prevalence of HHV-8 infection at the time of cohort enrollment was 25.9% (59/228). In the
univariate model, there were significant associations with male gender, black ethnicity, MSM practice, and previous hepatitis
B virus and syphilis infections. In the multivariate model we could still demonstrate association with MSM, hepatitis B, and
black ethnicity. No differences in mean CD4+ cell counts or HIV viral load according to HHV-8 status were found. In terms of
incidence, there were 23/127 (18.1%) seroconversions in the cohort after 1 year.
Conclusions: HHV-8 is highly prevalent among recently HIV-1-infected subjects. Correlations with other sexually transmitted
infections suggest common transmission routes.
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Introduction
Human herpesvirus-8 (HHV-8) infection is not always associ-
ated with clinical manifestations [1]. Nonetheless, when these
manifestations do occur, they can have a profound impact over
quality of life [2]. Kaposi’s sarcoma (KS) and other consequences
of HHV-8 are much more likely to arise in immunosuppressed
subjects, especially those HIV-infected. Therefore, studies of
prevalence of HHV-8 among HIV-infected patients are of prime
importance, as they can help estimate the risks of future co-
infection-derived complications [3].
HIV affects HHV-8 through different mechanisms. It is
debatable whether HIV Tat [4], inflammatory cytokines released
during HIV infection [5], or immunosuppression itself are the
main co-factors for the development of KS, but HIV has an
unquestionable predisposing effect for the conversion from
asymptomatic HHV-8 infection into clinical manifestations.
Besides, AIDS-KS is more aggressive and resistant to treatment
than other forms of KS [6]. HIV Tat activates lytic cycle
replication of HHV-8, via JAK/STAT signaling [7], or by
induction of HHV-8 Rta, a product of HHV-8 ORF 50 gene that
controls the transition from latency to lytic replication [8].
Co-infections also have several effects on the course and
progression of HIV. In this regard, the effects of HHV-8 infection
over HIV natural history are complex and still not entirely
elucidated [9]. Certain specific HHV-8 antigens such as LANA
(latency-associated nuclear antigen) can activate HIV [10], and
ORF 50, a lytic cycle gene, interacts with HIV Tat leading to
increased cell susceptibility to HIV infection [11,12]. HHV-8
stimulates HIV replication in acutely infected cells as well as
reactivation in chronically infected cells [9].
Lastly, the order and timing in which these two infections occur
can have prognostic implications. KS incidence is increased in
people who seroconvert to HHV-8 after HIV, with hazard ratios
of 2.55 [13] to 5.04 [3] and an additional risk of 1.6 in relation to
HIV-infected persons who were previously infected by HHV-8
[3].
Little is known about the prevalence and clinical correlates of
HHV-8 infection among recently HIV-infected individuals. We
studied these characteristics among 228 recently HIV-infected
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individuals recruited in Sao Paulo, Brazil. In addition, we
investigated the impact of HHV-8 co-infection over CD4+ T cell
count and HIV-viral load. Finally, we examined the incidence of
new HHV-8 seroconversions in this cohort after 1-year of follow-
up.
Methods
Ethics Statement
This research obtained approval by the Ethics Committee and
the Institutional Review Board of the Federal University of Sao
Paulo and patients provided informed consent.
Cohort description and laboratory measures
This study was performed in a cohort investigation that started
recruiting recently HIV-infected people in 2002 in Sao Paulo,
Brazil, aiming at the identification of host factors that contribute to
progression to immunodeficiency [14,15]. Recent HIV infection
was determined by the Serologic Testing Algorithm for Recent
HIV Seroconversion (STARHS), and individuals were included in
the study when they had a negative desensitized ELISA HIV-test,
that could indicate an incomplete antibody response as a
consequence of recent HIV infection [15]. There were 237
volunteers initially included in the cohort, but 9 were excluded due
to the presence of AIDS-defining conditions, representing false-
positive STARHS indication of recent infection. As a result, 228
volunteers were prospectively followed in the cohort. Individuals
were followed until the start of treatment, which happened when
the CD4+ T cell count dropped below 300 cells/ml or AIDS-
defining conditions developed.
Data on gender, age, ethnicity, mode of transmission, and
presence of symptoms were collected. We examined CD4+ and
CD8+ T cell counts and plasma HIV-1 RNA copies/ml at the
initial and subsequent visits. CD4+ and CD8+ T cell counts were
performed using a lymphocyte marking technique with anti- CD3,
CD4 and CD8 conjugated monoclonal antibodies (Kit TriTest,
BD Biosciences, San Diego, California, USA). The plasma RNA
measurements were performed using a Amplicor HIV-1 Monitor
test, version 1.5 (Roche Diagnostics, Indianapolis, IN, USA) until
January 2007, and was then subsequently replaced by the bDNA
(branched DNA) (VersantH - bDNA HIV-1 RNA 3.0 ASSAY,
Bayer Health Care LLC Tarrytown, NY). All individuals in the
cohort were tested for herpes simplex types 1 and 2, hepatitis B, C
and G by indirect ELISA (GBC ELISA provided by Dietmar
Zdunek, Roche Diagnostics, Germany; HSV-2 ELISA Diasorin,
Saluggia, Italy), syphilis (MHA-Tp and FTA-abs), CMV, EBV,
toxoplasmosis (Diasorin, Saluggia, Italy). HHV-8 serology was
performed retrospectively, with samples collected in the first visit
and after 1 year of follow-up. Table 1 summarizes cohort
epidemiological and demographic data.
Antibodies to latent and lytic HHV-8 antigens were detected
through an indirect immunofluorescence assay (IFA) based on the
BCBL-1 cell line [16,17]. Cells were grown in RPMI 1640 (Gibco
BRL) supplemented with 10% fetal calf serum, antibiotics
(penicillin and streptomycin), and amphotericin B. Cell cultures
were then washed three times with phosphate buffered saline
(PBS), resuspended in PBS and 10 mL of the suspension was
smeared onto slides, with a concentration of 106106 cells/ml. The
slides were air-dried and fixed for subsequent incubation for
30 minutes at 37uC with the test serum diluted at 1:80 and a goat
anti-human antibody fluorescein isothiocyanate-conjugate (Sigma
1:100 in PBS/ Evans blue milk 0.01 mg/ml); the slides were then
washed and dried. Punctuate nuclear staining was considered
positive for antibodies against LANA in untreated cells. For
induction of lytic replication, cells were treated with tetradecanoyl-
phorbol ester acetate. Whole cell fluorescence in more than 20%
of cells was considered positive for lytic antigens. Two researchers
read the slides independently, and indeterminate results were
repeated twice.
Statistical Analysis
Statistical analyses were performed using SPSS 16 software
(SPSS Inc., Chicago, Illinois, USA), with a minimum significance
level of p = 0.05. Initially, we performed a descriptive analysis of
demographic and laboratory results. Differences between groups
by HHV-8 status were analyzed using Chi-Square or Fisher’s
Exact Test. Multivariate analyses were performed by logistic
regression, with inclusion of variables with p#0.05, and analysis
by Hosmer and Lemeshow Test. We used the Mann-Whitney U-
Test to compare differences in continuous variables. Besides,
CD4+ T cell count and HIV viral load were also analyzed as
categorical variables using the median values to define groups.
The survival analysis was performed through a Kaplan-Meier
curve with CD4+ T cell count #350 as the main outcome. We
used the log-rank test to compare differences in the Kaplan Meier
survival functions according to HHV-8 status.
Results
The overall prevalence of antibodies against HHV-8 in the
cohort was 25.9% (59/228). Of those 59 seropositives, 12 (20.3%)
subjects were positive for latent and lytic antibodies concomitantly,
14 (23.7%) positive for LANA antibodies only, and 33 (55.9%) for
lytic antibodies only. In the univariate analysis, described in
Table 2, we were able to find correlations of HHV-8 infection with
male gender (27.5% male HHV-8+ vs. 9.5% female HHV-8+,
p = 0.05), MSM practice (28.7% MSM HHV-8+ vs. 10.8%
heterosexuals HHV-8+, p = 0.023), previous hepatitis B (anti-
hepatitis B core antibody) (19.7% anti-HBc-/HHV-8+ vs. 36.3%
anti HBc+/HHV-8+, p = 0.009), syphilis infection (MHA-Tp and
FTA-ABS) (23.5% syphilis-/HHV-8+ vs. 40% syphilis+/HHV-8+,
Table 1. Demographic and serologic characteristics of cohort
at initial visit.
Demographics - Number %
Gender Male 207 90.8
Female 21 9.2
Ethnicity White 129 58.4
Black 17 7.7
Mixed 44 19.9
Other 31 14
Exposure MSM 188 83.6
Heterosexual 37 16.4
Co-infections HSV-2 89/145 61.4
Anti-HBc 80/203 39.6
Syphilis 40/203 19.8
Variable - Median IQR 25–75%
CD4+ T cell count (cells/ml) - 529 403–709
Plasma HIV viral load (log10 copies/ml)- 4.26 3.59–4.81
Time to start on ART (days) - 412 153–694
doi:10.1371/journal.pone.0005613.t001
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p= 0.034), and black ethnicity (52.9% black/HHV-8+ vs. 29.5%
mixed/HHV-8+ vs. 19.4% white/HHV-8+, p = 0.021).
We then compared the median age using the Mann-Whitney
test and could not detect differences between the HHV-8
seronegative and seropositive groups (median = 31 in both groups,
p = 0.836), nor did we find differences among the median CD4+ T
cell counts and viral load values between the two groups in any of
the follow-up visits. Antiretroviral treatment was not initiated
more frequently in relation to HHV-8 status (24.9% treatment
negative/HHV-8+ vs. 29.1% treatment+/HHV-8+, p = 0.3), and
the median time until the start of antiretroviral treatment did not
vary between the two groups (median time to treatment in HHV-8
negative = 421 days vs. 405 days in HHV-8+, p = 0.9). In a
Kaplan-Meier survival analysis comparing HHV-8 positive and
negative individuals with CD4+ T cell count #350 cells/mm3 as
main outcome, there was no difference between groups by the log-
rank test (Figure 1). In the multivariate analysis, we could still
demonstrate association between HHV-8 status and MSM
exposure, hepatitis B and black ethnicity (Table 2).
We repeated the HHV-8 serology after 1-year follow-up in 127
of the 169 initially HHV-8-negative individuals. There were 23/
127 (18.1%) seroconversions in the cohort after one year. The 23
subjects who seroconverted after 1-year did not differ from the 59
HHV-8+ at the initial visit. In relation to the subjects who
remained negative after one year of follow-up, the only statistically
significant difference was observed in the time until start of
antiretroviral treatment (median time to treatment in HHV-8
negative subjects 245 vs. 573 days in HHV-8+, p = 0.045).
However, due to the fact that only 35 individuals initiated
treatment among the 127 tested after one year of follow-up, this
finding was not taken into further consideration.
Discussion
In this work, we found a significant proportion of recently HIV-
infected individuals who are seropositive for HHV-8 (25.9%
overall; 28.7% among MSM), which was consistent with reported
rates in HIV-1-infected subjects in Brazil, ranging from 14.6 to
18.7%, although higher among MSM (30.4 to 32.4%) [18,19,20].
An also high prevalence (32%) has been found in a group of
recently HIV-1-infected military members in the US [21]. Of
notice, we observed a correlation between HHV-8 and markers of
sexual activity, such as hepatitis B and syphilis. This provides
additional evidence for the hypothesis that risk behaviors
associated with HIV-1 and other sexually transmitted infections
(STIs) can also increase the probability for HHV-8 acquisition
[21]. Other studies have shown an association between HHV-8
and STIs, especially among MSM [22,23,24]. HHV-8 acquisition
has been associated with multiple sex partners in both MSM and
heterosexuals, and practices involving saliva are thought to
increase transmission, accounting for differences in incidence of
HHV-8 and HIV [25].
In addition, we were able to detect an association between black
ethnicity and HHV-8 in this cohort of recently HIV-infected
individuals. In fact, previous reports have described such
Table 2. Correlates of HHV-8 infection in study cohort.
Variable - Univariate Multivariate
OR* 95% CI** p OR* 95% CI** p
Ethnicity White 1.0 - - - - -
Black 4.680 (1.642, 13.343) 0.005 9.068 (2.478, 33.176) 0.018
Mixed 1.745 (0.799, 3.810) 0.160 1.556 (0.657, 3.684) 0.351
Other 1.447 (0.579, 3.614) 0.427 1.672 (0.604, 4.625) 0.361
Hepatitis B (anti-HBc seropositivity) (N/P) - 2.322 (1.227, 4.395) 0.009 2.230 (1.108, 4.488) 0.039
Syphilis (MHA-Tp) (N/P) - 2.175 (1.049, 4.512) 0.034 1.519 (0.662, 3.485) 0.324
HSV-2 (N/P) - 1.034 (0.494, 2.165) 0.929 - - -
Exposure MSM/hetero - 0.301 (0.102, 0.890) 0.023 0.176 (0.041, 0.079) 0.023
Gender M/F - 0.277 (0.063, 1.227) 0.054 3.841 (0.256, 57.519) 0.329
*OR: odds ratio.
**CI: confidence interval.
doi:10.1371/journal.pone.0005613.t002
Figure 1. Kaplan-Meier survival curves with CD4+ T cell count
#350 as the outcome. Legends: green line: HHV-8 negative; blue line:
HHV-8 positive green; +: HHV-8 negative censored blue; +: HHV-8
positive censored.
doi:10.1371/journal.pone.0005613.g001
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association between black ethnicity and HHV-8 in women
[26,27]. Although one study has found an association between
black ethnicity and protection against HHV-8 infection in men,
this was only observed among heterosexuals [21], different from
the present cohort, predominantly constituted by MSM. The
explanations for the difference in association between black
ethnicity and HHV-8 according to sexual orientation are unclear
and could again involve specific sexual practices [25].
The finding of 23/127 seroconversions after one year of follow-
up could indicate ongoing exposure of individuals after HIV
infection. HIV-infected subjects are at higher risk for HHV-8
seroconversion, and incident HHV-8 infection has been associated
with older age and multiple sexual partners, as well as orogenital
sexual practice and recreational drug use [28]. Incident HSV-2
infection has been previously assessed in 47 individuals from the
cohort, with a total of 10 (21.2%) seroconversions [29]. The
presence of incident co-infections supports the fact that HSV-2
and HHV-8 share common transmission routes in HIV-infected
persons. Besides, individuals who seroconverted to HHV-8 after
HIV are at a greater risk of subsequent development of KS [3,13].
Conversely, the lack of short term repercussion of HHV-8
infection over CD4+ T cell counts and plasma HIV viral load
during the observed follow-up period is in accordance with
previous evidence that HHV-8 has little influence on the
progression of HIV in initially asymptomatic individuals [30].
Indeed, we found that HHV-8 serostatus was not associated with
the need for antiretroviral treatment, nor with a shorter time until
the initiation of antiretroviral treatment.
HHV-8 serology was performed by immunofluorescence assays
against latent and lytic HHV-8 antigens. The association of assays
against latent and lytic antigens is prefered for asymptomatic
populations [31]. Immunofluorescence assays for latent phase
antibodies can have sensitivities ranging from 52 to 93%, yet these
values can be affected by low CD4+ T cell counts, especially under
100 cells/ml [32]. In this regard, most individuals in this cohort
had higher CD4+ T cell counts, as a result of their recent HIV
infection. The association of immunofluorescence for lytic phase
antibodies helped diminish this limitation. Although K8.1 EIA
would have further increased sensitivity, it could also decrease
specificity [33]. To add evidence to the aforementioned activating
effect of HIV on HHV-8 replication [4,5], we found that 45/59
(76.3%) of HHV-8-positive individuals had lytic phase antibodies.
In conclusion, HHV-8 infection is highly prevalent among
recently HIV-infected individuals. Significant associations with
sexually transmitted infections such as hepatitis B and syphilis add
evidence to the theory of a common transmission route. The
finding of a high incidence rate within the first year of follow-up of
this cohort points to an ongoing exposure behavior after HIV
acquisition. Safer sexual practices must be recommended to
decrease risks associated with co-infection.
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